ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

WSJ BLOG/Health: New Caution Urged Over Sole Oral MS Drug On the Market

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.) The FDA says the only oral multiple-sclerosis drug on the market -- Novartis's Gilenya -- shouldn't be used in patients with a recent history of stroke or some heart problems. As WSJ reports, a safety review of the treatment was prompted by a report in November of a 59-year-old patient dying in the U.S. less than a day after taking the first dose of the drug. Although the agency said an exact cause of the patient's death couldn't be identified, it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the treatment can lower a person's heart rate temporarily. Patients who have had a stroke or heart trouble within the past six months shouldn't take the drug, the FDA says. It also shouldn't be used in patients taking some kinds of medicines to treat heart arrhythmias. The FDA warning comes after Europe's drug regulator last month requested stronger safety warnings. The U.S. agency is currently reviewing another oral MS drug from Biogen Idec designed to work through a different mechanism than Gilenya. -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com.

Stock News for Novartis (NVS)
DateTimeHeadline
07/02/201503:48:47Ergomed Appoints Andrew Mackie as Chief Business Officer
06/29/201517:51:48ADRs End Lower; National Bank of Greece Drops Sharply
06/29/201503:39:07Novartis Buys Drug Development Company Spinifex Pharmaceuticals
06/24/201511:22:00Hagens Berman: Class Action Alleges Novartis Gleevec Patent Infringement...
06/22/201518:35:21ADRs End Higher; National Bank of Greece Rises
06/22/201507:47:44GlaxoSmithKline Sells Meningitis Vaccines to Pfizer For EUR115...
06/21/201511:06:03What Is Cancer Immunotherapy?
06/19/201511:38:07Novartis CEO: Roche Stake Would No Longer Have to Be Sold at...
06/18/201518:40:20ADRs End Higher; Telecom Italia Rises
06/18/201515:50:25Teva's Copaxone Patent Loses Again
06/17/201509:04:025 Healthcare Stocks for Dividend Lovers
06/14/201508:03:023 Big Healthcare Trends Wall Street Is Overlooking
06/13/201507:18:021 Drug Will Make or Break These 3 Biotech Stocks
06/10/201510:05:06Cancer Stocks: 2 to Sell, 1 to Buy
06/10/201510:05:06Cancer Stocks: 2 to Sell, 1 to Buy
06/10/201508:04:03Stocks to Watch in Animal Health: Zoetis and WOOF Lead the Pack
06/08/201519:01:02Google Inc Founder Sergey Brin Defends "Moonshots" to Shareholders
06/08/201507:24:023 Big Pharma Dividend Stocks That Are Dragging Down Your Returns
05/31/201513:03:02Stocks To Watch in Biotech
05/31/201510:19:03Why AbbVie, Inc. Is a Better Long-Term Buy Than Gilead Sciences...

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad